Thema
pembrolizumab
Case Reports
13
Diseases of the respiratory system
10
immune‐related adverse events
5
non‐small cell lung cancer
5
lung cancer
4
Biomarker
2
Chemoimmunotherapy
2
Gastritis
2
G‐CSF‐producing tumour
2
ICI
2
Immunotherapy
2
Lung cancer
2
Oesophagobronchial perforation
2
PD‐L1
2
Vogt–Koyanagi‐Harada disease
2
adenocarcinoma
2
cardiac metastasis
2
hypereosinophilia
2
immune checkpoint inhibitor
2
immune checkpoint inhibitors
2
immune‐related adverse event
2
inflammatory bowel disease
2
myositis
2
non‐small cell lung cancer‐not otherwise specified
2
pancreatitis
2
plasma exchange
2
pleomorphic carcinoma
2
pneumonia
2
pulmonary pleomorphic carcinoma
2
sclerosing cholangitis
2
self‐expanding metallic stent
2
thymoma
2
tumour marker
2
BRAF mutation
1
Immune checkpoint inhibitor
1
Lung adenocarcinoma
1
cardial tamponade
1
immunotherapy
1
non‐V600E genotype
1
non‐small cell lung cancer (NSCLC)
1
pericardial effusion
1
upper gastrointestinal disorder
1